Nearly 10 billion US dollars gene therapy market, attracting pharmaceutical companies have bets!

【Pharmaceutical Network Industry Dynamics】Gene therapy refers to the introduction of normal foreign genes into target cells through technical means, and the treatment of diseases
caused by genetic defects and abnormalities under the action of normal genes.
In recent years, with the increase in the incidence and incidence of various types of cancer, the global gene therapy market has ushered in rapid growth
.
The data shows that the global gene therapy market size will be $2.
3 billion in 2021 and is expected to grow
at a compound annual growth rate of 20.
8% during the forecast period from 2022 to 2030.
According to a new report by Nova One Advisor, the global gene therapy market is expected to reach about $8.
3 billion
by 2030.
In the face of the blue ocean of nearly 10 billion US dollars in the market, some multinational pharmaceutical companies with research and development strength have long had a layout
.
In 2017, the FDA approved the first gene therapy, and Kymriah, independently developed by Novartis, was approved for the treatment of acute lymphoblastic leukemia, followed by Kite Pharma's Yescarta for the treatment of large B-cell lymphoma, Spark Therapeutics' Luxturna for the treatment of hereditary normometrial lesions, and Novartis' Zolgensma for the treatment of children
with spinal muscular dystrophy under two years of age 。 Among them, Novartis' Zolgensma has generated sales
of $160 million in just four months since it was approved for listing in May 2019.
The potential of gene therapy drugs is huge, attracting more domestic and foreign pharmaceutical companies to bet
.
Recently, AstraZeneca and its subsidiary, Alexion Pharmaceuticals, agreed to acquire LogicBio Therapeu
for approximately $68 million (approximately 484 million yuan) for $2.
07 per share.
The latter is a clinical-stage genomic drug company that treats a variety of genetic diseases, including rare diseases, and is currently focusing on the development of novel gene therapies
for pediatric patients with rare diseases 。 In September, Hengrui Pharmaceutical issued an announcement that its subsidiary Shanghai Ruihongdi Pharmaceutical Co.
, Ltd.
intends to introduce Jiangsu Hengrui Pharmaceutical Group Co.
, Ltd.
, Shanghai Shengdi Biopharmaceutical Private Equity Investment Fund Partnership (Limited Partnership) and Shenzhen Yingtai Asset Management Co.
, Ltd.
as new shareholders through capital increase and share expansion, and the total capital increase of 3 companies is 498 million yuan.

。 According to the data, Shanghai Ruihongdi Pharmaceutical Co.
, Ltd.
focuses on the development of gene therapy drugs, and the research and development pipeline focuses on the fields of neurological, ophthalmology, metabolism, rare diseases, heart failure, tumors and other diseases, and it is expected that by 2024, there will be product pipelines for neurodegenerative diseases, ophthalmology and other diseases entering the clinical research stage
.
This capital increase is also considered to be a major move
for Hengrui to accelerate the layout of the gene therapy track.
However, due to the high barriers and high risk of gene therapy, in the immature stage of the domestic market, there are still relatively few local enterprises engaged in gene therapy and CRO companies that provide gene therapy-related outsourcing services, and the establishment time is relatively late, mainly including Northlander, Aoyuan Heli, Shengnuo Pharmaceutical, Bangyao Biological, Boya Jiyin, Zhongyin Technology, Ruifeng Biological, Fuyin Biologics, etc
.
Most of the pipeline projects of these entrants are in the early stages of clinical/clinical trials initiated by researchers, and it still takes a long time
for the products to be approved for marketing.
Capital is accelerating its entry and giving more support
to businesses on the track.
Among them, Heyuan Bio performed prominently, and the company completed a pre-C round of about 200 million yuan and a C round of financing
of more than 300 million yuan on July 7 and September 23, 2020, respectively.
The industry believes that the capital's attention to gene therapy next year may be expected to continue, optimistic about the progress
of enterprises on the track.
In general, compared with European and American countries, the ecological soil of the current gene therapy industry in China is still relatively "barren", and the industry suggests that it can overtake from the bottom two levels of "delivery technology" and "editing tools"
.
Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.